Centre mulls ‘Mission COVID Suraksha’ with Rs 3,000 cr corpusIllustrative image – not actual.
The Centre has proposed ‘Mission COVID Suraksha' to be set up with a corpus of nearly Rs 3,000 crore.

This will help in accelerating the process of developing and manufacturing safe and effective COVID-19 vaccines in the country that can be easily accessible and affordable for the public.

Piloted by the Department of Biotechnology, the proposed mission will focus on end-to-end vaccine development from clinical trial stage to regulatory facilitation to manufacturing.

The aim of the mission is to accelerate the development of at least six vaccine candidates and ensure that they are licensed and introduced in market for emergency use at the earliest.

According to the draft proposal, the mission has been proposed to have a timeline of 12 to 18 months. The proposed mission will also look to ensure that sufficient volumes are manufactured to meet India's COVID-19 vaccine requirement and to introduce it in public health systems of the Ministry of Health post the approval by the National Technical Advisory Group on Immunisation (NTAGI), to combat further spread of COVID-19 infection.

The proposed mission will work on an aggressive integrated plan of action for timely availability of resources, facilities and capabilities to avoid delays in development pathway, availability of expertise and technologies required for market entry and meeting the demand.

The proposed mission also aims to make available clinical trial sites, immunoassay laboratories, ensure all vaccine candidates being introduced through this programme have preferred characteristics applicable for India.

It also aims to support manufacturing capacity in the country for different vaccine platforms and ensure vaccine deployment and its uptake by the National Immunisation Programme.

Besides, it aims to work with indigenous and global candidates to ensure their successful trial and manufacture in the country.

India has nearly 30 vaccine candidates at different stages of vaccine development for coronavirus.

Currently, the two vaccine candidates indigenously developed by Bharat Biotech in collaboration with Indian Council of Medical Research (ICMR) and Zydus Cadila have moved to the Phase-II of human clinical trials.

Pune-based Serum Institute of India, which has partnered with AstraZeneca for manufacturing a COVID-19 vaccine candidate developed by the Oxford University, has been permitted for conducting Phase-II and III human clinical trials of the candidate in India. It is likely to start the trials soon.

In collaboration with HDT Biotech Corporation, USA, Gennova Biopharmaceuticals has also developed an mRNA vaccine candidate (HGCO19) and seed funding for it has been proposed by the Department of Biotechnology.

← All latest storiesBack to top →